Ajinomoto Builds Gene Therapy CDMO Capabilities Through $554m Forge Acquisition

 
• By Lisa Takagi

With an ambitious growth plan for its CDMO operations, Ajinomoto is planning to complete the acquisition of Forge Biologics Holdings by December, adding the US-based firm’s capabilities in gene therapy services.

Forge will join Ajinomoto's CDMO business as wholly-owned subsidiary.
Forge will join Ajinomoto's CDMO business as wholly-owned subsidiary • Source: Shutterstock

More from Business

More from Scrip